

11-755-C025

## Monoclonal Antibody to CD266 / TWEAK R Purified Antibody (0.025 mg)

<b>Clone:</b>	ITEM-4
<b>Isotype:</b>	Mouse IgG2b
<b>Specificity:</b>	The mouse monoclonal antibody ITEM-4 recognizes CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
<b>Regulatory Status:</b>	RUO
<b>Immunogen:</b>	human CD266-transfected P815 cells
<b>Species Reactivity:</b>	Human, Mouse
<b>Application:</b>	Flow Cytometry Western Blotting Immunohistochemistry (frozen sections) Functional Application blocking
<b>Purity:</b>	> 95% (by SDS-PAGE)
<b>Purification:</b>	Purified by protein-A affinity chromatography
<b>Concentration:</b>	1 mg/ml
<b>Storage Buffer:</b>	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
<b>Storage / Stability:</b>	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.

**For laboratory research only, not for drug, diagnostic or other use.**



**Antibodies**

- References:**
- \*Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. *J Immunol.* 2003 Jan 1;170(1):341-8.
  - \*Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. *Exp Ther Med.* 2011 Jan;2(1):103-108
  - \*Sanz AB, Sanchez-Ni&#241;o MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweek-induced apoptosis in PC-3 prostate cancer cells. *PLoS One.* 2012;7(10):e47440.
  - \*Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. *J Immunol.* 2010 Aug 1;185(3):1593-605.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at [www.exbio.cz](http://www.exbio.cz).

**For laboratory research only, not for drug, diagnostic or other use.**

---

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic  
Tel: +420 261 090 666 | Fax: +420 261 090 660 | [orders@exbio.cz](mailto:orders@exbio.cz) | [www.exbio.cz](http://www.exbio.cz)